Skip to main content

Table 2 DAS28 scores of mutant and non-mutant JAK2 RA patients

From: JAK2 mutation may predict response and guide first line treatment in rheumatoid arthritis

DAS28

Non-mutant JAK2

Mutant JAK2

X

P

Remission (≤ 2.6) (20 patients)

14 (70%)

6 (30%)

9.24

0.02

Low disease activity (≤ 3.2) (24 patients)

13 (54.2%)

11 (45.8%)

Moderate disease activity (3.2–5.1) (15 patients)

6 (40%)

9 (60%)

Severe disease activity (> 5.1) (26 patients)

7 (26.9%)

19 (73.1%)

  1. % in rows